We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom's Q2 revenues are expected to rise 12% year over year, supported by CGM demand and G7 15 Day adoption.
DXCM is seeing momentum from broader reimbursement, type 2 diabetes growth, and international expansion.
DXCM expects manufacturing gains and disciplined spending to support healthy earnings and cash generation.
DexCom, Inc. (DXCM - Free Report) is scheduled to report second-quarter 2026 results on July 30, after the closing bell.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 68 cents surpassed the Zacks Consensus Estimate by 19.15%.
Let us check out the factors that might have shaped DXCM’s performance prior to the announcement.
DXCM’s Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.3 billion, indicating an increase of 12% from the prior-year quarter’s level. The consensus mark for earnings is pinned at 61 cents, indicating growth 27.1% year over year.
DexCom is expected to have delivered another quarter of healthy revenue growth, supported by continued demand for continuous glucose monitoring (CGM) systems, expanding reimbursement, and sustained adoption of its recently launched G7 15 Day platform. Following a solid first quarter, management reiterated its full-year revenue outlook of 11-13% growth, citing strong momentum across both the U.S. and international markets, particularly in type 2 diabetes and expanding customer access.
The quarterly performance is likely to have benefited from increasing physician awareness of broader reimbursement coverage, especially for non-insulin type 2 patients, while continued conversion of existing users to the G7 15 Day system should have supported both volume growth and customer satisfaction.
Geographically, the U.S. business is expected to have remained driven by strong uptake in the type 2 diabetes market, aided by broader commercial coverage and improving field execution. On its first-quarter earnings call, management highlighted meaningful share gains among non-insulin type 2 patients and expects commercial coverage to exceed 7 million lives by year-end. The recently announced Prime Therapeutics reimbursement win could have begun contributing during the second quarter. International operations are also likely to have maintained robust momentum, supported by reimbursement expansions in markets such as France and Canada and continued tender wins, with additional access opportunities expected throughout the year.
New product execution should have remained an important growth catalyst. The G7 15 Day system, featuring longer sensor wear and an improved accuracy algorithm, has received positive physician and patient feedback, with nearly half of the installed base expected to transition to the platform by year-end. DexCom is also rolling out improved adhesive technology, expanding Smart Basal pilot deployments, and launching a redesigned Stelo application featuring AI-driven personalized insights and enhanced nutrition tracking, initiatives that should strengthen customer engagement and retention over time.
First-quarter gross margin expanded to 63.5%, benefiting from manufacturing efficiencies, normalized freight costs, supply-chain improvements, and the initial contribution from G7 15 Day. These factors are likely to have boosted margins in the second quarter as well. While management raised its full-year operating margin outlook, it maintained gross margin guidance due to uncertainty surrounding fuel prices, resin costs, and shipping conditions, implying some cost pressure could have emerged in the to-be-reported quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for DexCom this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (60 cents per share) and the Zacks Consensus Estimate, is -1.36%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2 at present.
DXCM’s Share Price Performance
So far this year, DexCom’s shares have gained 7.8% against the industry’s 15.5% decline. The S&P 500 has gained 7.5% during the said period.
Image Source: Zacks Investment Research
Stocks Worth a Look
Here are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #3 (Hold) at present. The company is scheduled to release second-quarter 2026 results on Aug. 4.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS implies an improvement of 10.9% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.
View the Zacks #1 Rank List
Image: Bigstock
DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion
Key Takeaways
DexCom, Inc. (DXCM - Free Report) is scheduled to report second-quarter 2026 results on July 30, after the closing bell.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 68 cents surpassed the Zacks Consensus Estimate by 19.15%.
Let us check out the factors that might have shaped DXCM’s performance prior to the announcement.
DXCM’s Q2 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.3 billion, indicating an increase of 12% from the prior-year quarter’s level. The consensus mark for earnings is pinned at 61 cents, indicating growth 27.1% year over year.
DexCom, Inc. Price and EPS Surprise
DexCom, Inc. price-eps-surprise | DexCom, Inc. Quote
Factors to Note Before DXCM’s Q2 Earnings
DexCom is expected to have delivered another quarter of healthy revenue growth, supported by continued demand for continuous glucose monitoring (CGM) systems, expanding reimbursement, and sustained adoption of its recently launched G7 15 Day platform. Following a solid first quarter, management reiterated its full-year revenue outlook of 11-13% growth, citing strong momentum across both the U.S. and international markets, particularly in type 2 diabetes and expanding customer access.
The quarterly performance is likely to have benefited from increasing physician awareness of broader reimbursement coverage, especially for non-insulin type 2 patients, while continued conversion of existing users to the G7 15 Day system should have supported both volume growth and customer satisfaction.
Geographically, the U.S. business is expected to have remained driven by strong uptake in the type 2 diabetes market, aided by broader commercial coverage and improving field execution. On its first-quarter earnings call, management highlighted meaningful share gains among non-insulin type 2 patients and expects commercial coverage to exceed 7 million lives by year-end. The recently announced Prime Therapeutics reimbursement win could have begun contributing during the second quarter. International operations are also likely to have maintained robust momentum, supported by reimbursement expansions in markets such as France and Canada and continued tender wins, with additional access opportunities expected throughout the year.
New product execution should have remained an important growth catalyst. The G7 15 Day system, featuring longer sensor wear and an improved accuracy algorithm, has received positive physician and patient feedback, with nearly half of the installed base expected to transition to the platform by year-end. DexCom is also rolling out improved adhesive technology, expanding Smart Basal pilot deployments, and launching a redesigned Stelo application featuring AI-driven personalized insights and enhanced nutrition tracking, initiatives that should strengthen customer engagement and retention over time.
First-quarter gross margin expanded to 63.5%, benefiting from manufacturing efficiencies, normalized freight costs, supply-chain improvements, and the initial contribution from G7 15 Day. These factors are likely to have boosted margins in the second quarter as well. While management raised its full-year operating margin outlook, it maintained gross margin guidance due to uncertainty surrounding fuel prices, resin costs, and shipping conditions, implying some cost pressure could have emerged in the to-be-reported quarter.
What the Zacks Model Unveils
Our proven model does not conclusively predict an earnings beat for DexCom this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (60 cents per share) and the Zacks Consensus Estimate, is -1.36%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2 at present.
DXCM’s Share Price Performance
So far this year, DexCom’s shares have gained 7.8% against the industry’s 15.5% decline. The S&P 500 has gained 7.5% during the said period.
Image Source: Zacks Investment Research
Stocks Worth a Look
Here are some stocks worth considering from the broader medical sector, as these have the right combination of elements to post an earnings beat this reporting cycle.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rankstocks here.
CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #3 (Hold) at present. The company is scheduled to release second-quarter 2026 results on Aug. 4.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS implies an improvement of 10.9% from the year-ago reported figure.
Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present.
A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS calls for an improvement of 8% from the year-ago reported figure.